Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 81Rheumatoid Arthritis Research and TherapiesComplementary and Alternative Medicine StudiesNatural Compounds in Disease Treatment

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Double-Blind, Randomized, Controlled, Pilot Study Comparing Classic Ayurvedic Medicine, Methotrexate, and Their Combination in Rheumatoid Arthritis

Furst, Daniel E., Venkatraman, Manorama M., McGann, Mary, Manohar, P. Ram, Booth-LaForce, Cathryn, Sarin, Reshmi, Sekar, P.G., Raveendran, K.G., Mahapatra, Anita, Gopinath, Jidesh, Kumar, P.R. Krishna·2011·JCR: Journal of Clinical Rheumatology
DOI 10.1097/rhu.0b013e31821c0310
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To compare classic Ayurveda, methotrexate (MTX), and their combination in a double-blind, randomized, double-dummy, pilot trial in rheumatoid arthritis (RA) for 36 weeks. METHODS: Forty-three seropositive RA patients by American College of Rheumatology (ACR) criteria with disease duration of less than 7 years were assigned to the following treatment groups: MTX plus Ayurvedic placebo (n = 14), Ayurveda plus MTX placebo (n = 12), or Ayurveda plus MTX (n = 17). Outcomes included the Disease Activity Score (DAS28-CRP), ACR20/50/70, and Health Assessment Questionnaire--Disability Index. All measures were obtained every 12 weeks for 36 weeks. Analyses included descriptive statistics, analysis of variance, χ², or Student t test. The unique features of this study included the development of placebos for each Ayurvedic pharmacological dosage form and individualization of Ayurvedic therapy. RESULTS: All groups were comparable at baseline in demographics and disease characteristics. There were no statistically significant differences among the 3 groups on the efficacy measures. ACR20 results were MTX 86%, Ayurveda 100%, and combination 82%, and DAS28-CRP response were MTX -2.4, Ayurveda -1.7, and combination -2.4. Differences in adverse events among groups were also not statistically significant, although the MTX groups experienced more adverse event (MTX 174, Ayurveda 112, combination 176). No deaths occurred. CONCLUSIONS: In this first-ever, double-blind, randomized, placebo-controlled pilot study comparing Ayurveda, MTX, and their combination, all 3 treatments were approximately equivalent in efficacy, within the limits of a pilot study. Adverse events were numerically fewer in the Ayurveda-only group. This study demonstrates that double-blind, placebo-controlled, randomized studies are possible when testing individualized classic Ayurvedic versus allopathic treatment in ways acceptable to western standards and to Ayurvedic physicians. It also justifies the need for larger studies.

Overview

Integrity signals

Registry

Crossref · 10.1097/rhu.0b013e31821c0310

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 4

  1. George, 1985, Ray of hope., WHO Bulletin, 112-, 116
  2. Venkatraman, 2002, Ayurveda: general principles and treatment of rheumatoid arthritis., Altern Med Alert, 5, 144
  3. Van Gestel, 1999, ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials., J Rheumatol, 26, 705
  4. Sander, 1998, Is H15 (extract of Boswellia serrata, "incense") an efficient supplementation to established drug therapy in RA? Results of a double blind pilot trial., J Rheumatol, 57, 11

Cited by

Related

See all

Metadata

Authors
Furst, D. E., Venkatraman, M. M., McGann, M., Manohar, P. R., Booth-LaForce, C., Sarin, R., Sekar, P. G., Raveendran, K. G., Mahapatra, A., Gopinath, J., & Kumar, P. R. K.
Affiliations
  • University of Washington (US)
  • University of California, Los Angeles (US)
  • King Edward Memorial Hospital and Seth G.S. Medical College (IN)
Corresponding author
  • McGann, Mary
  • Sekar, P.G.
ORCID
Kumar, P.R. Krishna
Venue
JCR: Journal of Clinical Rheumatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2011-06
Volume
17
Issue
4
Pages
185-192
ISSN
1076-1608 (ISSN-L)
DOI
10.1097/rhu.0b013e31821c0310
OpenAlex
W1970808527
Cited by
79
References
18
Citations by year
2026: 4 · 2025: 1 · 2024: 9 · 2023: 7 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 4 · 2015: 6 · 2014: 6 · 2013: 10 · 2012: 2
FWCI
4.89
Type
journal article
Language
en
Open access
closed
Locations
  • JCR Journal of Clinical Rheumatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r21at001969-03)
  • National Center for Complementary and Integrative Health (1 R21 AT-01969)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, Ayurveda, methotrexate, combination therapy, disease activity, ACR20 response, DAS28-CRP, HAQ-DI, adverse events
MeSH terms
Adult, Arthritis, Rheumatoid, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Medicine, Ayurvedic, Methotrexate, Middle Aged, Pilot Projects, Severity of Illness Index, Treatment Outcome, Outcome Assessment, Health Care, Antirheumatic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.